BMJ Open Effect of exercise on kidney-relevant biomarkers in the general population: a systematic review and meta-analysis

Qiaoling Liu ^(b), ¹ Carlos Celis-Morales ^(b), ^{1,2,3} Jennifer Lees, ¹ Patrick Mark, ¹ Paul Welsh¹

ABSTRACT

To cite: Liu Q, Celis-Morales C, Lees J, *et al.* Effect of exercise on kidney-relevant biomarkers in the general population: a systematic review and meta-analysis. *BMJ Open* 2025;**15**:e093017. doi:10.1136/ bmjopen-2024-093017

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (https://doi.org/10.1136/ bmjopen-2024-093017).

Received 30 August 2024 Accepted 19 November 2024



© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.

¹School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK ²Physical Activity and Health Research Unit, University Católica del Maule, Talca, Chile ³High-Altitude Medicine Research Centre (CEIMA), Universidad Arturo Prat, Iquique, Chile

Correspondence to Qiaoling Liu;

q.liu.3@research.gla.ac.uk

Objective Physical activity (PA) has been generally recognised as beneficial for health. The effect of a change in PA on kidney biomarkers in healthy individuals without kidney disease remains unclear. This manuscript synthesised the evidence of the association of changes in PA with kidney biomarkers in the general population free from kidney disease.

Design Systematic review and meta-analysis. **Data sources** Embase, PubMed, MEDLINE and Web of Science databases were searched from inception to 12 March 2023.

Eligibility criteria for selecting studies Studies of longitudinal or interventional design were selected initially. The following studies were excluded: (1) case-control studies, (2) studies where PA was measured at a single time point, (3) populations with known kidney disease, (4) studies evaluating the impact of a single episode/event of PA and (5) non-English language studies.

Data extraction and synthesis Two independent reviewers extracted data from a pre-designed table and assessed the risk of bias using the Cochrane Risk of Bias tool. Data were pooled using a random-effects model. Hedge's g was used to synthesise effect sizes and obtain an overall estimate. Heterogeneity between studies was measured using l². Funnel plots and Egger's test were performed to evaluate the risk of biased results.

Results 16 interventional studies with randomised or non-randomised designs involving 500 participants were identified. The median follow-up was 84 days. 10 studies were at high risk of bias. Studies with low quality were published prior to the year 2000. Changes in PA were found only to have a positive association with serum creatinine (SCr) (Hedge's g=0.69; 95% Cl 0.13, 1.24; l^2 =81.37%) and not with plasma renin activity (PRA), urea, or urine albumin-to-creatinine ratio (UACR). The positive association was only observed in people with obesity and those who exercised for more than 84 days.

Conclusions Higher levels of PA are associated with increased SCr levels in healthy people. It remains unclear if this association is related to impaired kidney function or gain in muscle mass, as data on other kidney biomarkers did not support a certain link.

PROSPERO registration number This review has been registered on PROSPERO (CRD42023407820).

STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ Different from existing studies that mainly focus on people with kidney diseases, this study focuses on populations without known kidney diseases, therefore extending the current knowledge.
- ⇒ This study analysed important kidney biomarkers, including serum creatinine, urine albumin-to-creatinine ratio and plasma renin activity, providing a broader understanding of the possible effect of changes in physical activity on kidney health.
- ⇒ Constrained by small sample sizes and heterogeneity, several included studies had limited population sizes and high attrition rates, which may lead to biases, particularly concerning the observed heterogeneity in outcomes.

BACKGROUND

Cardiovascular disease (CVD) is a major global health issue, causing approximately 17.9 million deaths annually, or 32% of all global fatalities as of 2019.¹ CVD also imposes a significant economic burden on health-care systems worldwide.^{2 3} Physical inactivity has been recognised as a risk factor for CVD events,^{4 5} while performing physical activity (PA) is beneficial to the prevention of CVD, along with other chronic conditions such as chronic kidney disease (CKD).⁶

Despite the myriad of benefits of PA on cardiovascular health, its effect on kidney function is not well established. Impaired kidney function is a risk factor for CVD;⁷ it is plausible that PA might also positively affect kidney function.⁸ Serum creatinine (SCr)-based estimated glomerular filtration rate is commonly used in clinical practice, and creatinine is a product of muscle metabolism.⁹ Therefore, any effect of PA on muscle metabolism may indirectly affect the measurement of kidney function. There is also evidence suggesting that extreme levels of PA may induce kidney damage via rhabdomyolysis or dehydration.¹⁰

Evidence from randomised controlled trials suggests that PA is associated with multiple metrics of kidney function. However, the evidence is controversial. PA is inversely associated with the risk of kidney function decline in people aged over 65, with an average estimated glomerular filtration rate (eGFR) of around $80 \text{ mL/min}/1.73 \text{ m}^{2.11}$ Yet, the same association was not observed in a younger general population (aged 26–65 years) with a much higher average eGFR of $108 \text{ mL/min}/1.73 \text{ m}^{2.12}$ Studies assessing PA intensity include data showing that accelerometer-measured low- and moderate-intensity PA is positively associated with eGFR in a general Japanese population (aged 35–79 years, average eGFR 92.6 mL/min/1.73 m²) across sexes and ages.¹³

PA has also been linked to urinary albumin excretion. As the dysfunction of the kidney endothelial barrier and atherosclerosis contribute to the leakage of albumin into the urine, microalbuminuria has been suggested as an indicator of kidney endothelial dysfunction.¹⁴ The association between high PA levels and lower microalbuminuria has been observed consistently across variant populations.¹⁵ Novel biomarkers of kidney impairment, such as liver-type fatty acid-binding protein, have also been found to be negatively impacted by habitual physical activities.¹⁶ The degree of stress on the proximal tubule may be attenuated through PA, regardless of the kidney's functional reserve, suggesting PA's health benefits on the kidney structure.

Although the effects of PA on the kidneys have been studied, many articles focus on the acute effect of PA, and they are not instructive of the impacts of changing habitual PA. The study population is often restricted to patients with CKD/end-stage kidney disease, including those who undergo dialysis. These research findings may not be applicable to the general population without known kidney disease. A number of intervention studies discussed the effect of PA in combination with other treatments, such as diet and pharmaceutical approaches; thus, it is difficult to measure PA's direct effect. To date, there is a lack of systematic reviews of the literature that have been conducted on the effect of changes in PA on kidney health in populations without pre-existing kidney diseases. In this context, this study aimed to conduct a systematic review and meta-analysis to bridge the knowledge gap.

METHODS

This review has been registered on PROSPERO (CRD42023407820). In this review, we followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement¹⁷ and the *Cochrane Handbook for Systematic Reviews of Interventions*.¹⁸ We followed the Population, Intervention, Comparison, Outcomes and Study framework to develop our search strategy.¹⁹ To be specific:

Population: Adults without known kidney disease. Intervention: PA.

Comparator: Kidney-relevant biomarkers before PA.

Outcome: Changes in kidney-relevant biomarkers after PA.

Study Design: Cohort or interventional study.

The research theme is: 'In adults without known kidney disease, to what extent does PA affect the levels of kidneyrelevant biomarkers compared with baseline levels?'

One author (QL) systematically searched Embase, PubMed, MEDLINE and Web of Science databases from inception to 12 March 2023. The inclusion criteria were (1) cohort studies or interventional studies (randomised/ non-randomised), (2) studies in which the duration and/or intensity of PA was measured at least twice and (3) studies in which the study population is based on the general population. It is expected that people with CKD will form around 10% of the general population, so we additionally extracted baseline eGFR and urine albumin-to-creatinine ratio (UACR) (where available) as an indicator of the baseline level of kidney function in these studies. We also carefully examined the description of the study population in selected studies. Studies that met the following criteria were excluded: (1) case-control studies, (2) studies in which PA was measured at a single time point, (3) studies conducted specifically in populations with pre-existing kidney diseases, such as CKD, dialysis and kidney transplantation, (4) studies evaluating the impact of a single episode of PA, such as a sporting event, and (5) studies that were not published in English. The detailed search terms can be found in the supplemental materials (online supplemental table S1).

Two authors (QL and PW) independently decided which studies should be included in this study, and any disagreements were resolved through a discussion with two other authors (CC and PM). To maximise the coverage of sources, one author (QL) checked the references of the selected articles and evaluated their relevance after reading the full text. Additively, one author (QL) performed manual searches for relevant studies.

Study exposure

The study exposure was the change in PA. The change in PA was denoted as a categorical variable, that is, from being sedentary to being active.

Study outcome

The primary study outcome was the change in kidneyrelevant biomarkers, including but not limited to SCr, cystatin C and UACR. This change was defined as the difference in a biomarker's level after the completion of a change in PA, for example, the difference in SCr levels before and after a 12-week aerobic exercise programme. In addition, long-term kidney outcomes, such as the first diagnosis of CKD and the presence of microalbuminuria, were also collected if relevant literature was identified.

Quality assessment

All the selected studies were interventional studies. The risk of bias for each selected study was assessed using the Cochrane Risk of Bias tool²⁰ by two reviewers

independently. Seven domains of bias (sequence generation, allocation concealment, blinding of participants and personnel/outcome assessment, incomplete outcome data, selective reporting and other biases) were assessed. The overall risk was categorised as low, high, critical, unclear or no information. A study was biased if the loss to follow-up was 20% or above.²¹ Any disparities in judgement raised between the two reviewers were resolved through discussion with the help of a third author as needed.

Data synthesis

Using a pre-designed table, information was extracted on the first author's family name, publication year, study type, study location, baseline characteristics of exercise groups, type of exercise, length/frequency/intensity of exercise and outcomes. In case a study has both exercise and sedentary groups, only the information of the group that performed PA was included to align with our research theme.

For studies with multiple measurements, we used the baseline and the final measurement to calculate the change. For example, if a kidney biomarker was measured at exercise week 0 (the baseline week), week 3 and week 6 (the final week), the change in the biomarker between week 0 and week 6 was used. In cases where subgroup findings were reported, those findings were extracted and compiled for meta-analysis, subject to data availability. The median (IQR) of reported data was converted to the mean (Standard Deviation [SD]) following established methods.²² In case the standard error of the mean (SEM) was provided only, the SD was calculated from SEM multiplied by the square root of the number of studies.

As between-study heterogeneity was anticipated, we constructed random-effects models²³ to combine the mean (SD) of selected studies and applied the inverse variance weighting method. The Hedge's g expresses the difference of the means in units of the pooled SD; it measures the effect size for the difference between the means. This study used it to synthesise effect sizes and obtain an overall estimate of the effect of PA. It incorporated a correction factor for small sample sizes, which is useful as many PA interventions were of small scale.²⁴ For interpretation, values of 0.2, 0.5 and 0.8 were regarded as small, medium and large effects, respectively.²⁵ Heterogeneity between studies was examined using the I^2 statistic, and an I² above 50% means substantial heterogeneity.^{26 27} Subgroup analyses and meta-regressions were conducted to investigate heterogeneity across age, obesity and length of exercise. Due to insufficient data, some subgroup analyses and regressions were not performed for all outcomes. Funnel plots and Egger's test were performed to evaluate the risk of biased results.²⁸ Statistical analyses were performed using STATA 17 (StataCorp, USA). Data were visualised using Robvis (https://mcguinlu.shinyapps.io/ robvis/).²⁹

Sensitivity analysis

Leave-one-out analysis was performed to identify influential studies by conducting the meta-analysis multiple times while removing one of the included studies during each iteration. Results were presented as leave-one-out figures. A cumulative meta-analysis was also performed for each outcome according to publication year to identify secular trends.

Patient and public involvement

It was not appropriate or possible to involve patients or the public in the design, or conduct, or reporting or dissemination plans of our research.

RESULTS

Identification of studies

After removing duplicated studies, 10294 potentially relevant studies were identified. Initial screening based on title and abstracts resulted in 155 studies retrieved for further evaluation. Following the full-text assessment, 150 studies were excluded, leaving 5 studies. Additionally, 20 studies were identified through hand search and reading citations, of which 9 were excluded, leaving 11 studies. In total, 16 studies were included for further analysis (online supplemental figure S1).

Characteristics of the included studies

All the 16 included studies were of interventional design. The duration of intervention ranged from 1 month to 9months, with a median duration of 2.8 months (11 weeks). The identified 16 studies have a total study population of 500 people (ranging from 4 to 162 individuals). The average age of participants was 50.1 years. 10 studies recruited people with essential hypertension,^{30–39} 1 study recruited people with type 2 diabetes mellitus,⁴⁰ 2 studies recruited people with obesity,^{41 42} 2 studies recruited healthy people⁴³ ⁴⁴ and 1 study recruited patients with heart failure.⁴⁵ Participants in 12 studies were required to perform aerobic exercise only^{30-39 44 45}; 2 studies involved aerobic exercise and its combinations with strength training,^{40 42} and 2 others involved resistance training only.^{41 43} All the studies have a similar exercise frequency of three to five sessions per week, while the length of sessions varies according to the exercise intensity, with a median of 12 weeks. Seven studies have an attrition rate of 20% or above, $^{30\,31\,33\,38\,39\,41\,42}$ with a maximum of $30.9\%.^{33}$

Eight studies used maximum oxygen uptake (VO_{2max}) to measure the intensity of aerobic exercise, ^{30 32 36-39'44 45} with a few studies using heart rate reserve, ³³ maximum heart rate^{34 35 42} and lactate threshold.^{31 40} For resistance and strength training, repetition maximum was used to measure the exercise intensity (online supplemental table S2).

Measurement of physical activities

14 studies required participants to perform on-site PA under close supervision. The low-workload group in the

study by Hagberg *et al*³⁰ was supervised for the first month and relied on self-reported forms for the remaining 8 months. All the participants in the study by Passino et al^{45} had self-conducted exercises with their compliance to the instructions checked at the beginning and near the end of the study. All the studies have reported the arrangement of physical training.

Measurement of the outcomes

SCr, plasma renin activity (PRA) and urea were the most measured biomarkers in selected studies. Two studies reported eGFR,^{36 42} one study⁴² reported urine albuminto-creatinine ratio (UACR) and one study³¹ was on angiotensin II (Ang II). Twelve of these studies measured fasting biomarkers, while 3 studies have not specified the fasting status^{42 44 45}; 1 study explicitly measured biomarkers after participants had 'a light breakfast'.³⁹ All the biomarkers were measured under resting conditions.

Potential bias and quality assessment

Overall, the selected studies have medium to low quality. Ten out of 16 studies were evaluated as having a high risk of bias. Most studies had a less representative cohort, especially those published decades ago, as early as in the 1980s.^{30 31} Studies with better population representation were published after 2000.^{41 42} The incomplete outcome data (attrition bias) were another major source of inferior quality, with seven studies having a high attrition rate of over 20%.^{30 31 33 38 39 41 42} It was impossible to blind participants in supervised situations due to the nature of the PA as an exposure. Considering the nature of the intervention design and the objective evaluation of outcomes through laboratory testing, all studies have a high risk for blinding of participants and personnel (performance bias) and a low risk for blinding of outcome assessment (detection bias). Six studies with a randomised design have provided information on how the random sequence was generated.^{30 38 40 42 43 45} Some studies also have a higher risk of measurement error for exposure and outcome (online supplemental table S3, figures 1 and 2).

Changes in physical activity and serum creatinine

The meta-analysis included six study populations from four studies,^{33 41-43} including 197 participants with an average PA duration of 73 days. The majority of findings



Figure 1 Summary of the risk of bias by the Cochrane Risk of Bias tool.

have a mean Hedge's g on the right side of the reference line with a wide 95% CI. The pooled result showed a moderate positive effect of PA on SCr (Hedge's g=0.69; 95% CI 0.13, 1.24). Substantial heterogeneity was detected among cohorts ($I^2=81.37\%$) (figure 3a).

Stratifying by obesity, only two groups of participants with obesity from a single study⁴² have a statistically significant pooled effect (Hedge's=0.74; 95% CI 0.29, 1.20). Stratified by the median of the length of exercises (12 weeks), only two cohorts from one study who have undergone exercise over 12 weeks have a significant pooled effect (Hedge's=0.74; 95% CI 0.29, 1.20) (online supplemental figure S2a,b).

The funnel plot showed mild asymmetry, and Egger's test showed no small-study effects (p value=0.21). Sensitivity analysis showed a consistent result as that of the primary analysis; the removal of one cohort from Zaman⁴¹ largely attenuated the pooled effect (Hedge's=0.38; 95% CI 0.05, 0.72). Obesity was identified as the only important source of heterogeneity. Cumulative meta-analyses according to the year of publication showed significant evidence of secular trends for SCr (online supplemental figure S2c-e).

Changes in physical activity and eGFR

Three cohorts from two studies, ^{36 42} which included 50 people with an average exercise duration of 12 weeks, were identified. No significant effect was found in the pooled result of the exercise on eGFR (Hedge's g=-0.30; 95% CI -0.83, 0.24; I²=48.57%) (figure 3b).

Changes in physical activity and urine albumin-to-creatinine ratio

Two cohorts from one study,⁴² which included 38 people with an average exercise duration of 3 months, were identified. No statistical significance was found in the pooled result of the exercise on UACR (Hedge's g=-0.15; 95% CI -0.59, 0.29) (figure 3c).

Changes in physical activity and plasma renin activity 13 cohorts from 11 studies^{30–32} ^{34–39} ⁴⁴ ⁴⁵ included 184 people with an average exercise duration of 129 days in the meta-analysis. No association between PA and PRA was observed (Hedge's g=-0.12; 95% CI -0.32, 0.09). Minor

High

Unclear

Low

		Risk of bias								
		D1	D2	D3	D4	D5	D6	D7	D8	Overall
	de Oliveira et al.[40], 2012	-	+	X		+	+	+	+	+
	Geyssant et al. [44], 1981			X		+	+	+	X	+
	Hagberg et al. [30], 1989	-	+	X		+	X	+	X	X
	Kinoshita et al. [36], 1991			X		+	+	+	+	+
	Kiyonaga et al. [31], 1985			X		+	X	+	+	X
	Koga et al. [37], 1992		X	X		+	+	+	+	X
	Martinelli et al. [34], 2010			X		+	+	+	+	+
ldy	Matsusaki et al. [38], 1992	-	+	X		+	X	+	+	X
Stu	Nelson et al. [39], 1986			X		+	X	+	X	X
	Passino et al. [45], 2006	-	+	X		+	+	+	X	X
	Sikiru and Okoye [33], 2014	X	X	X		+	X	+	+	X
	Sullivan et al. [35] , 1992			X		+	+	+	+	+
	Szulinska et al. [42], 2016	+	+	X		+	X	+	X	X
	Trabelsi et al. [43], 2012	-	X	X		+	+	+	+	X
	Urata et al. [32], 1987	-	+	X		+	+	+	+	+
	Zaman et al.[41], 2021	+	-	X		+	X	X	+	X
 D1: Random sequence generation (selection bias) D2: Allocation concealment (selection bias) D3: Blinding of participants and personnel (performance bias) D4: Blinding of outcome assessment (detection bias): Self-reported outcomes D5: Blinding of outcome assessment (detection bias): Objective measures D6: Incomplete outcome data (attrition bias): All outcomes D7: Selective reporting frequenting bias) 							es	Judgement High - Unclear Low Not applicable		





heterogeneity was found among cohorts ($I^2=2.54\%$) (figure 3d).

In stratified analyses, no associations were found in obesity status, exercise length, and age groups. There was no statistically significant effect of exercise on PRA in people aged 60 and above; the upper 95% CI was close to zero (Hedge's=-0.54; 95% CI -1.14, 0.06) (online supplemental figure S3a-c).

The funnel plot showed good symmetry. Egger's test showed no small-study effects (p value=0.39). Sensitivity analysis showed a consistently insignificant result as that of the primary analysis, with no influential single studies. Meta-regression showed no important sources of heterogeneity. Cumulative meta-analysis showed no significant changes in research findings (online supplemental figure S3d–f).

Changes in physical activity and serum urea

Five cohorts from three studies^{40 41 43} included 48 people with an average exercise duration of 73 days. No association was found between PA and urea (Hedge's g=-0.15; 95% CI -0.50, 0.20). No heterogeneity was found among

cohorts ($I^2=0.00\%$) (figure 3e). Data were consistent in subgroup analyses (online supplemental figure S4a).

The funnel plot showed good symmetry, and Egger's test showed no small-study effects (p value=0.39). Sensitivity analysis showed a consistently insignificant result as that of the primary analysis, with no influential single studies. Metaregression showed no important sources of heterogeneity. Cumulative meta-analyses showed no significant changes in research findings (online supplemental figure S4b–d).

Changes in physical activity and other kidney-related biomarkers

A study by Kiyonaga *et al*⁸¹ showed that after 20 weeks of mild aerobic exercise, the average level of angiotensin II in eight patients with essential hypertension increased significantly from 58 to 91 pg/mL. However, the increase in angiotensin II was not observed after completing the first 10 weeks of training.

DISCUSSION

In this systematic review and meta-analysis of 16 interventional studies involving 500 people without known kidney а

b

с

d

e Study de Oliveira e de Oliveira e de Oliveira e Trabelsi et a Zaman et al Overall Heterogenei Test of $\theta_i = \theta_i$

Study	Pre N	interve Mear	ention SD	Post-inte Mean	rvention SD	Hedges's g with 95% Cl
Trabelsi et al. [43] 2012	7	1.03	0.05	1.07	0.05	0.751_0.27.1.77
Sikiru and Okove [33]. 2014	112	0.81	0.03	0.85	0.39	0.13[-0.13_0.39
Szulinska et al. [42], 2016a	21	0.76	0.11	0.84	0.11	0.71 [0.10, 1.33
Szulinska et al. [42], 2016b	17	0.73	0.10	0.81	0.10	0.78 [0.10, 1.46
Zaman et al.[41], 2021a	20	0.90	0.19	0.91	0.32	0.04 [-0.57, 0.64
Zaman et al.[41], 2021b	20	1.03	0.06	1.12	0.02	1.97 [1.23, 2.72
Overall						0.69 [0.13, 1.24
Heterogeneity: $\tau^2 = 0.37$, $I^2 =$	81.37	%, H ² =	5.37			
Test of $\theta_i = \theta_j$: Q(5) = 25.14, Test of $\theta = 0$: $z = 2.43$, $p = 0$	p = 0.0	0				
rest of 0 = 0. 2 = 2.43, p = 0.	.02				1	0 10 20 30
Random-effects REML model Sorted by: year					-1.0	0 1.0 2.0 5.0
Study	Pre- N	interver Mean	ntion SD	Post-inte Mean	ervention SD	Hedges's g with 95% Cl
Kinoshita et al. [36], 1991	12	99.00	16.28	105.00	18.01	0.34 [-0.44. 1.12
Szulinska et al. [42], 2016a	21	129.47	33.24	114.02	24.98	-0.52 [-1.12, 0.09
Szulinska et al. [42], 2016b	17	143.91	36.69	124.65	26.71	-0.59 [-1.26, 0.08
Overall						-0.30 [-0.83, 0.24
Heterogeneity: $\tau^2 = 0.10$, $I^2 = 0.10$	45.87%	, H ² = 1	.85			
Test of $\theta = \theta_i$: Q(2) = 3.75, p =	= 0.15					
iestore = 0: z = -1.09, p = 0.	.28					
Random-effects REML model Sorted by: year						-1.0 U 1.0
Study	Pre- N	interver Mean	ntion F SD	Post-inter Mean	vention SD	Hedges's g with 95% Cl
Szulinska et al. [42], 2016a	21	1.19	2.32	1.28	2.42	0.04 [-0.56, 0.63
Szulinska et al. [42], 2016b	17	0.76	0.28	0.65	0.28 —	-0.38 [-1.05, 0.28
Overall						-0.15 [-0.59, 0.29
Heterogeneity: $\tau^2 = 0.00$, $I^2 =$	0.00%	$H^2 = 1$.00			
Test of $\theta_i = \theta_j$: Q(1) = 0.86, p	= 0.35					
lest of $\theta = 0$: z = -0.67, p = 0	0.51				T	
Random-effects REML model Sorted by: year					-1.0	-0.5 0 0.5
	Pre	-interve	ntion F	Post-inter	vention	Hedges's g
Study	Ν	Mean	SD	Mean	SD	with 95% Cl
Geyssant et al. [44], 1981	4	6.36	2.91	3.76	3.00 —	-0.77 [-2.03, 0.50
Kiyonaga et al. [31], 1985	9	1.10	1.20	1.30	0.90	= 0.10[-0.70, 1.00
Kiyonaga et al. [31], 1985 Nelson et al. [39], 1986	9 13	1.10 1.45	1.20 1.84	1.30 1.46	0.90 1.08	0.01 [-0.74, 0.75
Kiyonaga et al. [31], 1985 Nelson et al. [39], 1986 Urata et al. [32], 1987 Hashers et al. [30], 1989a	9 13 10	1.10 1.45 1.24	1.20 1.84 0.76	1.30 1.46 1.50	0.90 1.08 1.23	
Kiyonaga et al. [31], 1985 Nelson et al. [39], 1986 Urata et al. [32], 1987 Hagberg et al. [30], 1989a Hagberg et al. [30], 1989b	9 13 10 11	1.10 1.45 1.24 1.60 2.00	1.20 1.84 0.76 1.10	1.30 1.46 1.50 0.70 1.10	0.90 1.08 1.23 0.40 -	0.01 [-0.74, 0.75] 0.24 [-0.60, 1.03 -1.05 [-1.91, -0.18 -0.77 [-1.64, 0.11]
Kiyonaga et al. [31], 1985 Nelson et al. [39], 1986 Urata et al. [32], 1987 Hagberg et al. [30], 1989a Hagberg et al. [30], 1989b Kinoshita et al. [36], 1991	9 13 10 11 10 12	1.10 1.45 1.24 1.60 2.00 1.30	1.20 1.84 0.76 1.10 1.30 0.69	1.30 1.46 1.50 0.70 1.10 1.26	0.90 1.08 1.23 0.40 - 0.90 1.39	0.01 [-0.74, 0.74] 0.01 [-0.74, 0.74] 0.24 [-0.60, 1.03 -1.05 [-1.91, -0.14] 0.77 [-1.64, 0.11] -0.04 [-0.81, 0.74]
Kiyonaga et al. [31], 1985 Nelson et al. [39], 1986 Urata et al. [32], 1987 Hagberg et al. [30], 1989a Hagberg et al. [30], 1989b Kinoshita et al. [36], 1991 Sullivan et al. [35], 1992	9 13 10 11 10 12 15	1.10 1.45 1.24 1.60 2.00 1.30 1.90	1.20 1.84 0.76 1.10 1.30 0.69 1.16	1.30 1.46 1.50 0.70 1.10 1.26 1.94	0.90 1.08 1.23 0.40 - 0.90 1.39 1.55	0.10 [-0.74, 0.74 0.24 [-0.60, 1.03 -1.05 [-1.91, -0.14 -0.77 [-1.64, 0.17 -0.04 [-0.81, 0.77 -0.04 [-0.81, 0.77 -0.03 [-0.67, 0.77
Kiyonaga et al. [31], 1985 Nelson et al. [39], 1986 Urata et al. [32], 1987 Hagberg et al. [30], 1989a Hagberg et al. [30], 1989b Kinoshita et al. [36], 1991 Sullivan et al. [35], 1992	9 13 10 11 10 12 15 10	1.10 1.45 1.24 1.60 2.00 1.30 1.90 0.77	1.20 1.84 0.76 1.10 1.30 0.69 1.16 0.60	1.30 1.46 1.50 0.70 1.10 1.26 1.94 0.40	0.90 1.08 1.23 0.40 - 0.90 1.39 1.55 0.32	0.10 [-0.74, 0.74 0.24 [-0.60, 1.03 -1.05 [-1.91, -0.18 -0.77 [-1.64, 0.11 -0.04 [-0.81, 0.74 -0.03 [-0.67, 0.72 -0.74 [-1.61, 0.11
Kiyonaga et al. [31], 1985 Nelson et al. [39], 1986 Urata et al. [32], 1987 Hagberg et al. [30], 1989a Hagberg et al. [30], 1989b Kinoshita et al. [36], 1991 Sullivan et al. [35], 1992 Matsusaki et al. [38], 1992a	9 13 10 11 10 12 15 10 16	1.10 1.45 1.24 1.60 2.00 1.30 1.90 0.77 0.82	1.20 1.84 0.76 1.10 1.30 0.69 1.16 0.60 0.88	1.30 1.46 1.50 0.70 1.10 1.26 1.94 0.40 0.62	0.90 1.08 1.23 0.40 - 0.90 1.39 1.55 0.32 1.08	0.10 [0.74, 0.74 0.24 [-0.60, 1.03 -1.05 [-1.91, -0.18 -0.77 [-1.64, 0.11 -0.04 [-0.81, 0.74 -0.03 [-0.67, 0.72 -0.74 [-1.61, 0.11 -0.74 [-1.61, 0.11 -0.74 [-1.61, 0.11 -0.20 [-0.88, 0.48]
Kiyonaga et al. [31], 1985 Nelson et al. [39], 1986 Urata et al. [32], 1987 Hagberg et al. [30], 1989a Hagberg et al. [30], 1989a Kinoshita et al. [36], 1991 Sullivan et al. [35], 1992 Koga et al. [37], 1992 Matsusaki et al. [38], 1992b	9 13 10 11 10 12 15 10 16 10	1.10 1.45 1.24 1.60 2.00 1.30 1.90 0.77 0.82 1.26	1.20 1.84 0.76 1.10 1.30 0.69 1.16 0.60 0.88 0.47	1.30 1.46 1.50 0.70 1.10 1.26 1.94 0.40 0.62 1.47	0.90 1.08 1.23 0.40 - 0.90 1.39 1.55 0.32 1.08 0.51	0.10 [0.74, 0.74 0.24 [-0.60, 1.03 -1.05 [-1.91, -0.18 -0.77 [-1.64, 0.11 -0.04 [-0.81, 0.74 -0.03 [-0.67, 0.77 -0.74 [-1.61, 0.11 -0.74 [-1.61, 0.11 -0.77 [-1.64, 0.11 -0.04 [-0.81, 0.74 -0.74 [-1.61, 0.11 -0.74 [-1.61, 0.11 -0.72 [-0.88, 0.44 -0.74 [-1.61, 0.11 -0.72 [-0.88, 0.44 -0.74 [-0.64, 1.26 -0.74 [-0.64, 1.26] -0.75 [-0.88, 0.44 -0.75 [-0.88, 0.44] -0.75 [-0.88, 0.44] -0.75 [-0.88, 0.44] -0.75 [-0.88, 0.44] -0.75 [-0.88, 0.44] -0.75 [-0.88, 0.44] -0.75 [-0.44, 1.26] -0.75 [-0.44] -0.75 [-0.44] -0.75 [-0.44] -0.75 [-0.44] -0.75 [-0.44] -0.75 [-0.44] -0.75 [-0.44] -0.75 [-0.44] -0.75 [-0.44] -0.75 [-0.44] -0.75 [-0.44] -0.75 [-0.44] -0.75 [-0.44] -0.75 [-0.44] -0.75 [-0.44] -0.75 [-0.44] -0.75 [-0.44] -0.75 [-0.
Kiyonaga et al. [31], 1985 Nelson et al. [39], 1986 Urata et al. [32], 1987 Hagberg et al. [30], 1989a Hagberg et al. [30], 1989a Kinoshita et al. [36], 1991 Sullivan et al. [36], 1992 Koga et al. [37], 1992 Matsusaki et al. [38], 1992b Passino et al. [38], 2006	9 13 10 11 10 12 15 10 16 10 44	1.10 1.45 1.24 1.60 2.00 1.30 1.90 0.77 0.82 1.26 3.04	1.20 1.84 0.76 1.10 1.30 0.69 1.16 0.60 0.88 0.47 0.66	1.30 1.46 1.50 0.70 1.10 1.26 1.94 0.40 0.62 1.47 2.96	0.90 1.08 1.23 0.40 - 0.90 1.39 1.55 0.32 1.08 0.51 0.62	0.10 [-0.10, 10, 10, 10, 10, 10, 10, 10, 10, 10,
Kiyonaga et al. [31], 1985 Nelson et al. [39], 1986 Urata et al. [32], 1987 Hagberg et al. [30], 1989a Hagberg et al. [30], 1989a Kinoshita et al. [36], 1991 Sullivan et al. [36], 1992 Koga et al. [37], 1992 Matsusaki et al. [38], 1992a Matsusaki et al. [38], 1992b Passino et al. [45], 2006 Martinelli et al. [34], 2010	9 13 10 11 10 12 15 10 16 10 44 20	1.10 1.45 1.24 1.60 2.00 1.30 1.90 0.77 0.82 1.26 3.04 1.08	1.20 1.84 0.76 1.10 1.30 0.69 1.16 0.60 0.88 0.47 0.66 1.15	1.30 1.46 1.50 0.70 1.10 1.26 1.94 0.40 0.62 1.47 2.96 1.47	0.90 1.08 1.23 0.40 - 0.90 1.39 1.55 0.32 1.08 0.51 0.62 1.00	0.10 [-0.10, 10, 10, 10, 10, 10, 10, 10, 10, 10,
Kiyonaga et al. [31], 1985 Nelson et al. [39], 1986 Urata et al. [32], 1987 Hagberg et al. [30], 1989a Kinoshita et al. [30], 1989b Kinoshita et al. [36], 1991 Sullivan et al. [36], 1992 Matsusaki et al. [38], 1992a Matsusaki et al. [38], 1992b Passino et al. [45], 2006 Martinelli et al. [34], 2010	9 13 10 11 10 12 15 10 16 10 44 20	1.10 1.45 1.24 1.60 2.00 1.30 1.90 0.77 0.82 1.26 3.04 1.08	1.20 1.84 0.76 1.10 1.30 0.69 1.16 0.60 0.88 0.47 0.66 1.15	1.30 1.46 1.50 0.70 1.10 1.26 1.94 0.40 0.62 1.47 2.96 1.47	0.90 1.08 1.23 0.40 - 0.90 1.39 1.55 0.32 1.08 0.51 0.62 1.00	0.10 [0.74, 0.74 0.24 [-0.60, 1.03 -1.05 [-1.91, -0.14 -0.77 [-1.64, 0.17 -0.04 [-0.81, 0.77 -0.03 [-0.67, 0.72 -0.74 [-1.61, 0.12 -0.20 [-0.88, 0.44 -0.12 [-0.28, 0.24 -0.35 [-0.26, 0.93 -0.12 [-0.32, 0.05
Kiyonaga et al. [31], 1985 Nelson et al. [39], 1986 Urata et al. [39], 1987 Hagberg et al. [30], 1989a Hagberg et al. [30], 1989b Kinoshita et al. [36], 1991 Sullivan et al. [36], 1992 Matsusaki et al. [38], 1992a Matsusaki et al. [38], 1992a Passino et al. [45], 2006 Martinelli et al. [34], 2010 Overall Heterogeneity: $r^2 = 0.00$, $r^2 =$	9 13 10 11 10 12 15 10 16 10 44 20 2.54%	1.10 1.45 1.24 1.60 2.00 1.30 1.90 0.77 0.82 1.26 3.04 1.08 $H^2 = 1$	1.20 1.84 0.76 1.10 1.30 0.69 1.16 0.60 0.88 0.47 0.66 1.15	1.30 1.46 1.50 0.70 1.10 1.26 1.94 0.40 0.62 1.47 2.96 1.47	0.90 1.08 1.23 0.40 - 0.90 1.39 1.55 0.32 1.08 0.51 0.62 1.00	0.10 [0.74, 0.74 0.24 [-0.60, 1.03 -1.05 [-1.91, -0.14 -0.77 [-1.64, 0.17 -0.04 [-0.81, 0.74 -0.05 [-0.88, 0.44 -0.12 [-0.54, 0.22 -0.74 [-1.61, 0.13 -0.20 [-0.88, 0.44 -0.41 [-0.44, 1.22 -0.35 [-0.26, 0.93 -0.12 [-0.32, 0.05
Kiyonaga et al. [31], 1985 Nelson et al. [39], 1986 Urata et al. [32], 1987 Hagberg et al. [30], 1989a Hagberg et al. [30], 1989b Kinoshita et al. [36], 1991 Sullivan et al. [35], 1992 Matsusaki et al. [38], 1992 Matsusaki et al. [38], 1992 Passino et al. [38], 1992b Passino et al. [38], 2006 Martinelli et al. [34], 2010 Overall Heterogeneity: $\tau^2 = 0.00, t^2 =$ Test of $\theta = \theta; Q(12) = 14.86$.	9 13 10 11 10 12 15 10 16 10 44 20 2.54% .p = 0.2	1.10 1.45 1.24 1.60 2.00 1.30 1.90 0.77 0.82 1.26 3.04 1.08 $, H^2 = 1.25$	1.20 1.84 0.76 1.10 1.30 0.69 1.16 0.60 0.88 0.47 0.66 1.15	1.30 1.46 1.50 0.70 1.10 1.26 1.94 0.40 0.62 1.47 2.96 1.47	0.90 1.08 1.23 0.40 - 0.90 1.39 1.55 0.32 1.08 0.51 0.62 1.00	0.10 [0.74, 0.74 0.01 [0.74, 0.74 0.24 [-0.60, 1.03 -1.05 [-1.91, -0.14 -0.77 [-1.64, 0.17 -0.04 [-0.81, 0.77 -0.74 [-1.61, 0.13 -0.20 [-0.88, 0.44 -0.12 [-0.54, 0.22 -0.12 [-0.54, 0.23 -0.12 [-0.32, 0.08
Kiyonaga et al. [31], 1985 Nelson et al. [39], 1986 Urata et al. [32], 1987 Hagberg et al. [30], 1989a Hagberg et al. [30], 1989a Kinoshita et al. [38], 1991 Sullivan et al. [35], 1992 Matsusaki et al. [38], 1992a Matsusaki et al. [38], 1992b Passino et al. [38], 1992b Passino et al. [38], 1992b Matsusaki et al. [38], 2006 Martinelli et al. [34], 2010 Overall Heterogeneity: $r^2 = 0.00$, $l^2 =$ Test of $\theta = \theta$; Q(12) = 14.86, Test of $\theta = 0$; z = -1.14, p = 0	9 13 10 11 10 12 15 10 16 10 44 20 2.54% , p = 0.2	1.10 1.45 1.24 1.60 2.00 1.30 1.90 0.77 0.82 1.26 3.04 1.08 $H^2 = 1$	1.20 1.84 0.76 1.10 1.30 0.69 1.16 0.60 0.88 0.47 0.66 1.15	1.30 1.46 1.50 0.70 1.10 1.26 1.94 0.40 0.62 1.47 2.96 1.47	0.90 1.08 1.23 0.40 - 0.90 1.39 1.55 0.32 1.08 0.51 0.62 1.00	0.10 [0.74, 0.74 0.24 [-0.60, 1.03 -1.05 [-1.91, -0.14 -0.77 [-1.64, 0.17 -0.04 [-0.81, 0.77 -0.74 [-1.61, 0.13 -0.03 [-0.67, 0.77 -0.74 [-1.61, 0.13 -0.20 [-0.88, 0.44 -0.12 [-0.54, 0.22 0.35 [-0.26, 0.97 -0.12 [-0.32, 0.05 -0.12 [-0.32, 0.05
Kiyonaga et al. [31], 1985 Nelson et al. [39], 1986 Urata et al. [39], 1987 Hagberg et al. [30], 1989a Hagberg et al. [30], 1989a Kinoshita et al. [36], 1991 Sullivan et al. [36], 1992 Koga et al. [37], 1992 Matsusaki et al. [38], 1992a Matsusaki et al. [38], 1992a Matsusaki et al. [38], 1992b Passino et al. [45], 2006 Martinelli et al. [34], 2010 Overall Heterogeneity: $r^2 = 0.00$, $l^2 =$ Test of $\theta = \theta$; $z = -1.14$, $p = 0$ Random-effects REML model Sorted by: vear	9 13 10 11 10 12 15 10 16 10 44 20 2.54% 2.54%	1.10 1.45 1.24 1.60 2.00 1.30 1.90 0.77 0.82 1.26 3.04 1.08 H ² = 1. 25	1.20 1.84 0.76 1.10 1.30 0.69 1.16 0.60 0.88 0.47 0.66 1.15	1.30 1.46 1.50 0.70 1.10 1.26 1.94 0.40 0.62 1.47 2.96 1.47	0.90 1.08 1.23 0.40 - 0.90 1.39 1.55 0.32 1.08 0.51 0.62 1.00	-1.0 0 1.0 -1.0 0 1.0
Kiyonaga et al. [31], 1985 Nelson et al. [39], 1986 Urata et al. [32], 1987 Hagberg et al. [30], 1987 Hagberg et al. [30], 1989a Kinoshita et al. [38], 1998 Sullivan et al. [35], 1992 Matsusaki et al. [38], 1992a Matsusaki et al. [38], 1992b Passino et al. [37], 1992 Matsusaki et al. [38], 1992b Passino et al. [38], 2006 Martinelli et al. [34], 2010 Overall Heterogeneity: $r^2 = 0.00$, $l^2 =$ Test of $\theta = \theta_i$: Q(12) = 14.86, Test of $\theta = 0$: z = -1.14, p = 0 Random-effects REML model Sorted by: year	9 13 10 11 10 12 15 10 16 10 44 20 2.54% 2.54% Prec	1.10 1.45 1.24 1.60 2.00 1.30 1.90 0.77 0.82 1.26 3.04 1.08 H ² = 1. 25	1.20 1.84 0.76 1.10 1.30 0.69 1.16 0.60 0.88 0.47 0.66 1.15 03	1.30 1.46 1.50 0.70 1.10 1.94 0.40 0.62 1.47 2.96 1.47	0.90 1.08 1.23 0.40 - 0.90 1.39 1.55 0.32 1.08 0.51 0.62 1.00 -2.0	-1.0 0 1.0 Hedges's g
Kiyonaga et al. [31], 1985 Nelson et al. [39], 1986 Urata et al. [32], 1987 Hagberg et al. [30], 1989 Hagberg et al. [30], 1989a Kinoshita et al. [36], 1991 Sullivan et al. [36], 1992 Koga et al. [37], 1992 Matsusaki et al. [38], 1992a Matsusaki et al. [38], 1992a Matsusaki et al. [38], 1992b Passino et al. [45], 2006 Martinelli et al. [34], 2010 Overall Heterogeneity: $r^2 = 0.00$, $r^2 =$ Test of $\theta = \theta$; Q(12) = 14.86, Test of $\theta = 0$; z = -1.14, p = 0 Random-effects REML model Sorted by: year	9 13 10 11 10 12 15 10 16 10 44 20 2.54% .p=0.2 5 .25	1.10 1.45 1.24 1.60 2.00 1.30 1.90 0.77 0.82 1.26 3.04 1.08 H ² = 1. 25	1.20 1.84 0.76 1.10 1.30 0.69 1.16 0.60 0.88 0.47 0.66 1.15 03	1.30 1.46 1.50 0.70 1.10 1.26 1.94 0.40 0.40 0.40 0.42 1.47 2.96 1.47	0.90 1.08 1.23 0.40 -0.90 1.39 1.55 0.32 1.08 0.51 0.62 1.00 -2.0 rvention	-1.0 0 1.0 -1.0 0 1.0 -1.0 0 1.0 -1.0 0 1.0 Hedges's g with 95% CI
Kiyonaga et al. [31], 1985 Nelson et al. [39], 1986 Urata et al. [32], 1987 Hagberg et al. [30], 1989a Hagberg et al. [30], 1989b Kinoshita et al. [36], 1991 Sullivan et al. [35], 1992 Koga et al. [37], 1992 Matsusaki et al. [38], 1992a Matsusaki et al. [38], 1992b Passino et al. [45], 2006 Martinelli et al. [34], 2010 Overall Heterogeneity: $τ^2 = 0.00$, $t^2 = 14.86$, Test of θ = 0; z = -1.14, p = 0 Random-effects REML model Sorted by: year Study de Oliveira et al. [40], 2012a	9 13 10 11 10 12 15 10 16 10 44 20 2.54% .p = 0.: 2.52 N N	1.10 1.45 1.24 1.60 2.00 1.30 1.90 0.77 0.82 1.26 3.04 1.28 H ² = 1. 25 	1.20 1.84 0.76 1.10 1.30 0.69 1.16 0.60 0.88 0.47 0.66 1.15 03	1.30 1.46 1.50 0.70 1.10 1.26 1.47 2.96 1.47 2.96 1.47 2.96 1.47 2.96 1.47	0.90 1.08 1.23 0.40 0.90 1.39 1.55 0.32 1.08 0.51 0.62 1.00 rvention SD	-1.0 0 1.0 Hedges's g with 95% CI -0.17 [-0.98, 0.64
Kiyonaga et al. [31], 1985 Nelson et al. [39], 1986 Urata et al. [32], 1987 Hagberg et al. [30], 1989a Hagberg et al. [30], 1989b Kinoshita et al. [36], 1991 Sullivan et al. [36], 1992 Matsusaki et al. [38], 1992 Matsusaki et al. [38], 1992 Matsusaki et al. [38], 1992b Passino et al. [45], 2006 Martinelli et al. [34], 2010 Overall Heterogeneity: $τ^2 = 0.00$, $t^2 = 1$ Test of θ = 0; $z = -1.14$, $p = 0$ Random-effects REML model Sorted by: year Study de Oliveira et al. [40], 2012a de Oliveira et al. [40], 2012a	9 13 10 11 10 12 15 10 16 10 16 10 44 20 2.54% N Prec N 11 10 12 15 10 16 10 12 15 10 10 12 15 10 10 12 15 10 10 12 15 10 10 12 15 10 10 12 15 10 16 10 10 12 15 10 16 10 10 12 15 10 16 10 10 12 15 10 16 10 10 12 15 10 16 10 10 10 10 10 10 10 10 10 10	1.10 1.45 1.24 1.60 2.00 1.30 1.90 0.77 0.82 1.26 3.04 1.08 $H^2 = 1.25$ -interve Mean 29.27 31.00	1.20 1.84 0.76 1.10 1.30 0.69 1.16 0.66 0.47 0.66 1.15 03 03	1.30 1.46 1.50 0.70 1.10 1.26 1.47 2.96 1.47 2.96 1.47 2.96 1.47 2.98 2.90	0.90 1.08 1.23 0.40 0.90 1.39 1.55 0.32 1.08 0.51 0.62 1.00 rvention SD 6.36 - 2.0	-1.0 0 1.0 Hedges's g with 95% Cl -1.0 0 1.0 Hedges's g
Kiyonaga et al. [31], 1985 Nelson et al. [39], 1986 Urata et al. [32], 1987 Hagberg et al. [30], 1988a Hagberg et al. [30], 1988a Hagberg et al. [30], 1989b Kinoshita et al. [36], 1991 Sullivan et al. [35], 1992 Matsusaki et al. [38], 1992 Matsusaki et al. [38], 1992 Passino et al. [38], 1992b Passino et al. [38], 1992b Passino et al. [34], 2010 Overall Heterogeneity: $\tau^2 = 0.00$, $t^2 =$ Test of $\theta = 0$; $z = .1.14$, $p = 0$ Random-effects REML model Study de Oliveira et al.[40], 2012a de Oliveira et al.[40], 2012b de Oliveira et al.[40], 2012b	9 13 10 11 10 12 15 10 16 10 16 10 44 20 2.54% N Prec N 11 10 12 15 10 16 10 12 15 10 10 12 15 10 10 12 15 10 10 12 15 10 10 12 15 10 10 12 15 10 16 10 10 12 15 10 16 10 10 12 15 10 16 10 10 12 15 10 16 10 10 16 10 10 16 10 10 10 10 10 10 10 10 10 10	1.10 1.45 1.24 1.60 2.00 1.30 1.90 0.77 0.82 1.26 3.04 1.08 H ² = 1. 25 	1.20 1.84 0.76 1.10 0.69 1.16 0.60 0.88 0.47 0.66 1.15 03	1.30 1.46 1.50 0.70 1.10 1.26 1.94 0.40 0.62 1.47 2.96 1.47 2.96 1.47 2.818 29.90 35.20	0.90 1.08 1.23 0.40 - 0.90 1.39 1.55 0.32 1.08 0.51 0.62 1.00 	-1.0 0 1.0 Hedges's g with 95% Cl -1.0 0 1.0 Hedges's g with 95% Cl -1.0 0 1.0 -1.0 0.02 [-0.34, 0.74 -0.04 [-0.81, 0.74 -0.05 [-1.91, -0.14 -0.07 [-1.64, 0.12 -0.74 [-1.61, 0.13 -0.20 [-0.88, 0.44 -0.41 [-0.44, 1.22 -0.35 [-0.26, 0.93 -0.12 [-0.32, 0.05 -0.12 [-0.32, 0.05 -0.17 [-0.98, 0.66 -0.11 [-0.96, 0.66 -0.11 [-0.96, 0.75 -0.08 [-0.76, 0.75] -0.08 [-0.76, 0.75 -0.08 [-0.76, 0.75] -0.08 [-0.76,
Kiyonaga et al. [31], 1985 Nelson et al. [39], 1986 Urata et al. [32], 1987 Hagberg et al. [30], 1988a Hagberg et al. [30], 1989b Kinoshita et al. [36], 1991 Sullivan et al. [35], 1992 Matsusaki et al. [38], 1992 Passino et al. [43], 2006 Overall Heterogeneity: $r^2 = 0.00$, $l^2 =$ Test of $\theta = 0$; Q(12) = 14.86, Test of $\theta = 0$; Z = -1.14, p = 0 Random-effects REML model Study de Oliveira et al.[40], 2012a de Oliveira et al.[40], 2012 Trabelsi et al.[40], 2012 Tastelsi et al.[41], 2012	9 13 10 11 10 12 15 10 16 10 44 20 2.54% P rec N 11 10 10 7 20	1.10 1.45 1.24 1.60 2.00 1.30 1.90 0.77 0.82 1.26 3.04 1.08 H ² = 1. 29.27 31.00 34.40 27.06 3.33	1.20 1.84 0.76 1.10 0.69 1.16 0.60 0.88 0.47 0.66 1.15 03 5.93 10.56 9.91 1.92 3.57	1.30 1.46 1.50 0.70 1.10 1.26 1.94 0.40 0.62 1.47 2.96 1.47 2.96 1.47 2.86 2.96 3.520 2.7.00 2.227	0.90 1.08 1.23 0.90 1.23 0.90 1.23 0.90 1.39 0.51 0.62 1.00 -2.0 rvention SD 6.36 -8.82 9.40 1.56 2.26 2.45 2.4	-1.0 0 1.0 Hedges's g with 95% CI -1.0 0 1.0 Hedges's g -1.0 0 1.0 -1.05 [-0.7] -1.0 0 1.0 -1.05 [-0.7] -1.0 0 1.0 -1.05 [-0.7] -0.74 [-1.61, 0.7] -0.74 [-1.61, 0.7] -0.75 [-1.74 [-1.74 [-1.74 [-1.74 [-1.74 [-1.74 [-1.74 [-1.74 [-1.74 [-1.74 [-1.74 [-1.
kiyonaga et al. [31], 1985 Nelson et al. [39], 1986 Urata et al. [32], 1987 Hagberg et al. [30], 1989a Hagberg et al. [30], 1989b Kinoshita et al. [38], 1991 Sullivan et al. [35], 1992 Matsusaki et al. [38], 1992a Matsusaki et al. [38], 1992b Passino et al. [38], 1992b Passino et al. [38], 1992b Passino et al. [38], 1992b Passino et al. [38], 1992b Matsusaki et al. [38], 1992b Passino et al. [38], 1992b Passino et al. [38], 1992b Passino et al. [38], 1992b Passino et al. [40], 2010 Overall Heterogeneity: $r^2 = 0.00$, $r^2 =$ Test of θ = 0; $z = -1.14$, $p = 0$ Random-effects REML model Sorted by: year Study de Oliveira et al. [40], 2012a de Oliveira et al. [40], 2012c Trabelsi et al. [40], 2012 Zaman et al. [41], 2021a Overall	9 13 10 11 10 12 15 10 16 10 44 20 2.54% Prec N 11 10 0.25 Prec N 20 2.54% 11 10 10 10 10 10 10 10 10 10	1.10 1.45 1.24 1.60 2.00 0.30 1.30 1.90 0.77 0.82 1.26 3.04 1.08 $H^2 = 1.25$ 29.27 31.00 34.40 27.06 33.33	1.20 1.84 0.76 1.10 1.30 0.69 1.16 0.60 0.88 0.47 0.66 1.15 03	1.30 1.46 1.50 0.70 1.26 1.94 0.40 0.62 1.47 2.96 1.47 2.96 1.47 2.818 28.18 28.90 35.20 27.00 32.27	0.90 1.08 1.23 0.40 1.39 1.55 0.32 1.08 0.51 0.62 1.00 rvention SD 0.63 -2.0 0.51 0.62 1.00 1.00 -2.0 0.00 -2.0	-1.0 0 1.0 Hedges's g with 95% Cl -1.0 0 1.0 Hedges's g 0.12 [-0.32, 0.05 -1.0 0 1.0 Hedges's g 0.12 [-0.32, 0.05 -0.12 [-0.32, 0.05 -0.12 [-0.54, 0.22 -1.0 0 1.0 Hedges's g 0.35 [-0.26, 0.97 -0.12 [-0.54, 0.22 -0.12 [-0.32, 0.05 -0.12 [-0.50, 7.07 0.08 [-0.76, 0.92 -0.03 [-0.76, 0.92 -0.76, 0.92
Kiyonaga et al. [31], 1985 Nelson et al. [39], 1986 Urata et al. [32], 1987 Hagberg et al. [30], 1989a Hagberg et al. [30], 1989b Kinoshita et al. [38], 1991 Sullivan et al. [38], 1991 Sullivan et al. [38], 1992 Matsusaki et al. [38], 1992 Matsusaki et al. [38], 1992b Passino et al. [45], 2006 Martinelli et al. [38], 1992b Passino et al. [45], 2000 Overall Heterogeneity: $\tau^2 = 0.00, t^2 = 1.4.86$, Test of $\theta = \theta$; Q(12) = 14.86, Test of $\theta = 0$; $z = -1.14, p = 0$ Random-effects REML model Sorted by: year <u>Study</u> de Oliveira et al. [40], 2012a de Oliveira et al. [40], 2012b de Oliveira et al. [40], 2012c Trabelsi et al. [40], 2012c Zaman et al. [41], 2021a Overall Heterogeneity: $\tau^2 = 0.00, t^2 = 1.4.86$, Test of $\theta = 0$; $z = -1.14, p = 0$	9 13 10 11 10 12 15 10 16 10 44 20 2.54% p = 0.2 0.25 Pree N 11 10 7 20 0.00%	1.10 1.45 1.24 1.60 2.00 1.30 1.40 1.30 1.40 1.30 1.40 1.30 1.40 1.30 1.40	1.20 1.84 0.76 1.10 1.30 0.69 1.16 0.69 1.16 0.88 0.47 0.66 1.15 03 5.93 10.56 9.91 1.92 3.57	1.30 1.46 1.50 0.70 1.10 1.26 1.47 2.96 1.47 2.8.6 1.47 2.8.18 2.9.90 35.20 27.00 32.27	0.90 1.08 1.23 1.23 0.40 1.39 1.55 0.32 1.08 0.51 0.62 1.00 	-1.0 0 1.0 Hedges's g with 95% Cl -1.0 0 1.0 -1.05 [-0.94, 0.74 -0.04 [-0.81, 0.77 -0.74 [-1.61, 0.13 -0.02 [-0.88, 0.44 -0.12 [-0.54, 0.22 -0.12 [-0.54, 0.22 -1.0 0 1.0 Hedges's g with 95% Cl -0.17 [-0.98, 0.64 -0.17 [-0.98, 0.64 -0.17 [-0.98, 0.64 -0.17 [-0.98, 0.64 -0.11 [-0.95, 0.77 0.08 [-0.76, 0.92 -0.03 [-1.01, 0.92 -0.03 [-1.01, 0.92 -0.03 [-0.10, 0.95 -0.02 [-0.50, 0.22 -0.15 [-0.50, 0.22 -0.15 [-0.50, 0.22
Kiyonaga et al. [31], 1985 Nelson et al. [39], 1986 Urata et al. [32], 1987 Hagberg et al. [30], 1987 Hagberg et al. [30], 1989a Kinoshita et al. [38], 1998 Sullivan et al. [38], 1991 Sullivan et al. [35], 1992 Matsusaki et al. [38], 1992a Matsusaki et al. [38], 1992a Matsusaki et al. [38], 1992b Passino et al. [37], 1992 Heterogeneity: $r^2 = 0.00$, $l^2 =$ Test of $\theta = \theta$; Q(12) = 14.86, Test of $\theta = \theta$; Q(12) = 14.86, Test of $\theta = \theta$; Q(12) = 14.86, Test of $\theta = 0$; Z = -1.14, p = C Random-effects REML model Sorted by; year Study de Oliveira et al. [40], 2012a de Oliveira et al. [40], 2012a Trabelsi et al. [40], 2012a Zaman et al. [41], 2021a Overall Heterogeneity: $r^2 = 0.00$, $l^2 =$ Test of $\theta = \theta$; Q(4) = 0.71, p	9 13 10 11 10 12 15 10 16 10 16 10 44 20 2.54% Pre N 11 10 10 7 20 0.00%, = 0.95	1.10 1.45 1.24 1.60 2.00 1.30 1.30 0.77 0.82 1.26 3.04 1.08 H ² = 1. 29.27 31.00 34.40 27.06 33.33 H ² = 1.	1.20 1.84 0.76 1.10 1.30 0.69 1.16 0.86 0.47 0.66 1.15 03 5.93 5.93 10.56 9.91 1.92 3.57	1.30 1.46 1.50 0.70 1.10 1.26 1.94 0.40 0.62 1.47 2.96 1.47 2.96 1.47 2.96 1.47 2.88 2.90 2.818 2.90 3.5.20 3.5.20 3.5.20	0.90 1.08 1.23 0.40 1.39 1.55 0.32 1.08 0.51 0.62 1.00 -2.0 rvention SD 6.36 - 8.82 - 2.54 -	-1.0 0 1.0 Hedges's g with 95% Cl -1.0 0 1.0 -1.05 [-0.98, 0.44 -0.12 [-0.32, 0.05 -1.0 0 1.0 Hedges's g with 95% Cl -0.12 [-0.98, 0.44 -0.12 [-0.32, 0.05 -0.12 [-0.32, 0.05 -0.11 [-0.98, 0.45 -0.12 [-0.32, 0.05 -0.12 [-0.32, 0.05 -0.11 [-0.98, 0.45 -0.11 [-0.98, 0.45 -0.12 [-0.32, 0.05 -0.12 [-0.32, 0.05 -0.11 [-0.98, 0.45 -0.11 [-0.98, 0.45 -0.11 [-0.98, 0.45 -0.11 [-0.98, 0.45 -0.11 [-0.98, 0.45 -0.11 [-0.98, 0.45 -0.12 [-0.32, 0.05 -0.12 [-0.32, 0.05 -0.15 [-0.50, 0.25 -0.15 [-0.50, 0.25 -0.15 [-0.50, 0.25
Kiyonaga et al. [31], 1985 Nelson et al. [39], 1986 Urata et al. [32], 1987 Hagberg et al. [30], 1989a Hagberg et al. [30], 1989a Kinoshita et al. [36], 1991 Sullivan et al. [35], 1992 Koga et al. [37], 1992 Matsusaki et al. [38], 1992a Matsusaki et al. [38], 1992a Matsusaki et al. [38], 1992b Passino et al. [45], 2006 Martinelli et al. [34], 2010 Overall Heterogeneity: $r^2 = 0.00, r^2 =$ Test of $\theta = \theta$; Q(12) = 14.86, Test of $\theta = \theta$; Q(12) = 14.80, Test of $\theta = \theta$; Q(12) = 14.80, Test of $\theta = \theta$; Q(12) = 14.80, Test of $\theta = \theta$; Q(12) = 12, Trabelsi et al. [40], 2012c Trabelsi et al. [40], 2012c Trabelsi et al. [40], 2012c Zaman et al. [41], 2021a Overall Heterogeneity: $r^2 = 0.00, r^2$ Test of $\theta = \theta$; Q(4) = 0.71, p Test of $\theta = 0$; z = .0.85, p = 0.	9 13 10 11 10 12 15 10 16 10 44 20 2.54% p = 0.2 0.25 Pre N 11 10 10 2.54% 0.25 .0 .0 .0 .0 .0 .0 .0 .0 .0 .0	1.10 1.45 1.24 1.60 2.00 1.30 1.90 0.77 0.82 1.26 3.04 1.26 3.04 1.26 3.04 1.25 -interve Mean 29.27 31.00 34.40 27.06 3.33 H ² = 1.	1.20 1.84 0.76 1.10 1.30 0.69 1.16 0.60 0.88 0.47 0.66 1.15 03	1.30 1.46 1.50 0.70 1.10 1.26 1.94 0.62 1.47 2.96 1.47 2.96 1.47 2.86 1.47 2.818 29.90 35.20 35.20 32.27	0.90 1.08 1.23 0.40 - 1.39 1.55 0.32 1.08 0.51 0.62 1.00 rvention <u>SD</u> 6.36 - 8.82 9.40 1.56 - 2.54	-1.0 0 1.0 Hedges's g with 95% Cl -1.0 0 1.0 Hedges's g with 95% Cl -1.0 1.0 -1.0 1.0 -1.0 0 1.0 -1.0 1.0 -0.02 [-0.32, 0.02 -0.12 [-0.32, 0.02 -0.12 [-0.32, 0.02 -0.12 [-0.32, 0.02 -0.11 [-0.98, 0.44 -0.11 [-0.98, 0.44 -0.12 [-0.32, 0.02 -0.12 [-0.32, 0.02 -0.12 [-0.32, 0.02 -0.13 [-0.10, 0.92 -0.03 [-1.01, 0.92 -0.03 [-1.01, 0.92 -0.03 [-1.01, 0.92 -0.03 [-1.01, 0.92 -0.03 [-1.01, 0.92 -0.03 [-1.01, 0.92 -0.03 [-0.10, 0.92 -0.03 [-0.10, 0.92 -0.15 [-0.50, 0.20 -0.15 [-0.50, 0.20
Kiyonaga et al. [31], 1985 Nelson et al. [39], 1986 Urata et al. [32], 1987 Hagberg et al. [30], 1989a Hagberg et al. [30], 1989b Kinoshita et al. [36], 1991 Sullivan et al. [35], 1992 Koga et al. [37], 1992 Matsusaki et al. [38], 1992a Matsusaki et al. [38], 1992a Matsusaki et al. [38], 1992b Passino et al. [45], 2006 Martinelli et al. [34], 2010 Overall Heterogeneity: $\tau^2 = 0.00$, $t^2 =$ Test of $\theta = \theta$; Q(12) = 14.86, Test of $\theta = 0$; z = -1.14, p = 0 Random-effects REML model Sortied by: year Study de Oliveira et al. [40], 2012a de Oliveira et al. [40], 2012b de Oliveira et al. [40], 2012c Trabelsi et al. [41], 2012a Overall Heterogeneity: $\tau^2 = 0.00$, $t^2 =$ Test of $\theta = \theta$; Q(4) = 0.71, p : Test of $\theta = 0$; z = -0.85, p = 0	$\begin{array}{c} 9\\ 13\\ 10\\ 11\\ 10\\ 12\\ 15\\ 10\\ 16\\ 10\\ 44\\ 20\\ 2.54\%\\ P=0.2\\ 2.5\\ \hline \\ Pre\\ N\\ 11\\ 10\\ 10\\ 10\\ 7\\ 20\\ 0.00\%, = 0.95\\ .40\\ \end{array}$	1.10 1.45 1.24 1.60 2.00 1.30 1.90 0.77 0.82 1.26 3.04 1.26 1.26 3.04 1.26 3.03 3.04 1.27 3.03 1.27 3.03 1.27 3.03 1.27 3.03 1.27 3.03 1.27 3.03 1.27 3.03 1.27 3.03 1.27 3.03 1.27 3.03 1.27 3.03 1.27 3.03 1.27 3.03 1.27 3.03 1.27 3.03 1.27	1.20 1.84 0.76 1.10 1.30 0.69 1.16 0.60 0.88 0.47 0.66 1.15 03	1.30 1.46 1.50 0.70 1.26 1.94 0.62 1.47 2.96 1.47 2.96 1.47 2.86 1.47 2.818 29.90 35.20 35.20 32.27	0.90 1.08 1.23 0.40 - 1.39 1.55 0.32 1.08 0.51 0.62 1.00 rvention SD 6.36 - 2.54 - 1.65 - 2.54	-1.0 0 1.0 Hedges's g with 95% Cl -1.0 0 1.0 Hedges's g with 95% Cl -1.0 0 1.0 -1.0 0 1.0 -1.0 0 1.0 -1.0 0 0.0 -1.0 0 0.0 -0.12 [-0.32, 0.05 -0.12 [-0.32, 0.05 -0.12 [-0.32, 0.05 -0.12 [-0.32, 0.05 -0.11 [-0.98, 0.64 -0.11 [-0.98, 0.76 -0.12 [-0.32, 0.05 -0.15 [-0.50, 0.20 -0.15 [-0.50, 0.20] -0.15 [-0.50, 0.20 -0.15 [-0.50, 0.20] -0.15 [-0.50

Figure 3 Meta-analysis on the associations of changes in physical activity (PA) with kidney-relevant biomarkers: (a) serum creatinine; (b) estimated glomerular filtration rate; (c) urine albumin-to-creatinine ratio; (d) plasma renin activity; (e) urea. Note: Szulinska et al:⁴² patients received endurance training. Szulinska et al:⁴² patients received both endurance and strength training. Zaman et al:41 patients with obesity. Zaman et al:41 patients without obesity. Hagberg et al:30 patients performed lowintensity PA. Hagberg et al:³⁰ patients performed moderate-intensity PA. Matsusaki et al:³⁸ patients performed low-workload PA. Matsusaki et al.³⁸ patients performed high-workload PA. de Oliveira et al.⁴⁰ patients performed aerobic training. de Oliveira et al:⁴⁰ patients performed strength training. de Oliveira et al:⁴⁰ patients performed aerobic and strength training. Zaman et al:⁴¹ patients with obesity. REML, Restricted maximum likelihood.

diseases, we evaluated the available data exploring the association of change in PA with kidney function. Change in PA was found only to have a positive association with SCr, not with eGFR. There was some limited evidence that participants with obesity and people who exercised for more than 12 weeks may have a larger increase in SCr as compared with their counterparts. Sensitivity analysis was in line with the primary analysis; mild publication bias and a secular trend were found. The general quality of studies was suboptimal to make robust conclusions, and the number and size of studies were generally small (ranging from 4 to 112 participants).

Due to the possibility of PA inducing muscle growth, which is the primary source of SCr, the role of body composition in the association between PA and SCr deserves discussion. Among three studies reporting on SCr and body composition, Szulinska *et al*⁴² reported a significant increase in lean body mass and SCr, and a decrease in body fat% in a population receiving endurance and strength training for 3 months; Trabelsi et al⁴³ reported no significant changes in body fat% but a significant increase in SCr in a population receiving 1-month resistance training, while Sikiru et al³³ reported no significant change in body fat% and a likely increase in SCr in a population receiving 8 weeks of aerobic training. It is noteworthy that the study populations of the above studies had markedly different body compositions, with the latter two having low baseline body fat%, that is, 11.9% and 13.5%, respectively, while the population in the first study had an average body fat% of over 33%. Additionally, Kinoshita *et al*^{$\delta 6}$ reported no significant change in eGFR</sup> in 12 non-obese people after a 10-week aerobic exercise, which implied a possible insignificant change in SCr. Therefore, the impact of PA on SCr levels may be related to body composition.

In the pooled result, there was no statistically significant association of exercise with UACR (figure 3c). The pooled result came from two cohorts of one study with a small study population.⁴² It should be noted that while urinary albumin and urinary creatinine both increased after endurance-strength training, their ratio did not change much, implying a balanced increase of albumin and creatinine. In people who only performed endurance training, no increases in albumin, creatinine or UACR were found. Therefore, the increase in albumin and creatinine might be caused by increased muscle mass or post-activity proteinuria.

As an important hormone secreted by the kidney for regulating blood pressure, renin has long been a topic of interest. Among the biomarkers under discussion, renin is the most extensively researched, with the earliest studies dating back to the 1980s. However, 9 of the 11 studies on renin were published in 1992 or earlier, with only 2 published after 2000. The studies involved a small number of participants, with most having between 10 and 20 individuals. Nevertheless, the cumulative meta-analysis based on publication year revealed a progressively narrowing 95% CI with an upper limit approaching zero and a consistently negative effect size. In the research conducted by Matsuaki et al,³⁸ despite the absence of a significant difference in baseline PRA between the low- $(50\%\,\mathrm{VO}_{_{2\mathrm{max}}})$ and the high-workload $(75\%\,\mathrm{VO}_{_{2\mathrm{max}}})$ group, both cohorts manifested a similar pattern characterised by two interlocking M shapes throughout six measurements conducted at baseline and week 1/2/4/7/10. The PRA pattern exhibited by the low-workload group between week 1 and week 10 was similar to that of the high-workload group between week 0 and week 7. The PRA change in the low-workload group was 'delayed' by 1 week compared with the high-workload group. Specifically, the PRA in the low-workload group experienced a slight decline in the first week, followed by an increase in the second week, whereas the PRA in the high-workload group increased in the first week. The underlying mechanism of this finding remains elusive.

Kiyonaga *et al*^{β 1} reported a significant increase in angiotensin II after 20 weeks of mild aerobic exercise in eight patients, yet no significant increase was observed by week 10. As renin secretion is the first step in the production of angiotensin II, it can be speculated that exercise lasting over 20 weeks may significantly impact renin (and thus angiotensin II). Renin is rarely measured in clinical practice and is affected by many antihypertensive drugs. Although these findings are interesting, any effect of PA on renin is unlikely to translate into information used to inform clinical guidelines.

Urea is clinically measured to evaluate kidney impairment, although to a lesser degree than SCr. There was a lack of a significant association between exercise and urea levels. One possible explanation is that considering the absence of kidney disease in all study participants at baseline, the closely supervised, low to moderate-intensity exercise did not result in kidney damage or alterations that exceeded the kidney compensation, thus precluding significant observable variations in urea levels.

To the best of our knowledge, this is the first systematic review and meta-analysis to investigate the association between changes in PA and kidney biomarkers in people without known kidney disease. The studies included underwent rigorous assessment based on strict criteria. We observed low heterogeneity among most of the biomarkers studied. Sensitivity analyses aligned with our primary findings.

It is unlikely that any rise in SCr with PA represents an adverse effect of PA on kidney function, given the widespread benefits of PA on cardiovascular health. It is theoretically plausible that PA reduces glomerular perfusion and, hence, creatinine rises. This effect is seen in people taking both medications inhibiting the renin-angiotensin system⁴⁶ and sodium-glucose transporter 2 inhibitors.⁴⁷ This transient rise in SCr is associated with long-term cardiovascular and kidney benefits with these agents. Studies of PA with long durations are required to determine if any change in creatinine with PA is associated with benefits or harm on cardiorenal health. Although efforts have been made in this study, there are several limitations. First, most studies had a very small sample size, with only a few exceptions. This may, in part, be attributed to a general insufficiency of resources, such as funding and personnel. Second, over 50% of the studies were found to have considerable bias, primarily stemming from high attrition rates, negatively impacting the quality of these studies. Finally, some studies were conducted decades ago, which could introduce potential issues with measurement methods, accuracy and lab standards. This underscores the pressing requirement for updated and standardised research.

In conclusion, by examining the changes in PA among individuals without diagnosed kidney disease, the findings of this study supported the positive association of PA with SCr. However, the association with kidney function specifically could not be confirmed by existing data on other kidney biomarkers. Given the global advocacy for increased PA by governments and medical professionals and the clinical importance of kidney function, further research should be conducted in the general population to investigate the association of changes in PA with kidney function.

Contributors Conceptualisation: PW, QL; Methodology: QL; Data curation: QL, PW, CC-M, PM; Writing—original draft preparation: QL; Writing—review and editing: QL, PW, CC-M, JL, PM; Supervision: PW, CC-M, PM; Critical revision for important intellectual content: PW, CC-M, JL, PM. All authors have read and agreed to the published version of the manuscript. QL is the guarantor.

Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. JL is personally funded by a Wellcome Trust Early Career Award (301005/Z/23/Z).

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting or dissemination plans of this research.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs

Qiaoling Liu http://orcid.org/0000-0003-2109-3974 Carlos Celis-Morales http://orcid.org/0000-0003-2612-3917

REFERENCES

- World Health Organization. Cardiovascular diseases (cvds). Available: https://www.who.int/news-room/fact-sheets/detail/cardiovasculardiseases-(cvds) [Accessed 24 Apr 2023].
- 2 Gheorghe A, Griffiths U, Murphy A, et al. The economic burden of cardiovascular disease and hypertension in low- and middle-income countries: a systematic review. BMC Public Health 2018;18:975.
- 3 Tajeu GS, Ruiz-Negrón N, Moran AE, et al. Cost of Cardiovascular Disease Event and Cardiovascular Disease Treatment-Related Complication Hospitalizations in the United States. *Circ Cardiovasc Qual Outcomes* 2024;17:e009999.
- 4 Lavie CJ, Ozemek C, Carbone S, et al. Sedentary Behavior, Exercise, and Cardiovascular Health. Circ Res 2019;124:799–815.
- 5 Bellettiere J, LaMonte MJ, Evenson KR, et al. Sedentary behavior and cardiovascular disease in older women: The Objective Physical Activity and Cardiovascular Health (OPACH) Study. *Circulation* 2019;139:1036–46.
- 6 Hayden CMT, Begue G, Gamboa JL, *et al.* Review of Exercise Interventions to Improve Clinical Outcomes in Nondialysis CKD. *Kidney Int Rep* 2024;9:3097–115.
- 7 Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, *et al.* Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. *Lancet* 2010;375:2073–81.
- 8 Park S, Lee S, Kim Y, *et al.* Causal effects of physical activity or sedentary behaviors on kidney function: an integrated population-scale observational analysis and Mendelian randomization study. *Nephrol Dial Transplant* 2022;37:1059–68.
- 9 Inker LA, Eneanya ND, Coresh J, et al. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N Engl J Med 2021;385:1737–49.
- 10 Rawson ES, Clarkson PM, Tarnopolsky MA. Perspectives on Exertional Rhabdomyolysis. *Sports Med* 2017;47:33–49.
- 11 Kim H, Ko MJ, Lim C-Y, et al. Association between physical activity and risk of renal function decline and mortality in communitydwelling older adults: a nationwide population-based cohort study. BMC Geriatr 2022;22:973.
- 12 Herber-Gast G-CM, Hulsegge G, Hartman L, *et al.* Physical Activity Is not Associated with Estimated Glomerular Filtration Rate among Young and Middle-Aged Adults: Results from the Population-Based Longitudinal Doetinchem Study. *PLoS ONE* 2015;10:e0133864.
- 13 Sasaki S, Nakamura K, Ukawa S, et al. Association of accelerometermeasured physical activity with kidney function in a Japanese population: the DOSANCO Health Study. BMC Nephrol 2022;23:7.
- 14 Prasad RM, Bali A. Microalbuminuria. In: StatPearls, ineligible companies. Disclosure: Atul Bali declares no relevant financial relationships with ineligible companies. Disclosure: Richa Tikaria declares no relevant financial relationships with ineligible companies. Treasure Island (FL): StatPearls Publishing, 2024.
- 15 Vittori LN, Romasco J, Tarozzi A, et al. Urinary Markers and Chronic Effect of Physical Exercise. *Methods Mol Biol* 2021;2292:193–200.
- 16 Kosaki K, Kamijo-Ikemori A, Sugaya T, et al. Effect of habitual exercise on urinary liver-type fatty acid-binding protein levels in middle-aged and older adults. Scand J Med Sci Sports 2018;28:152–60.
- 17 Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71.
- 18 McKenzie JE, Brennan SE, Ryan RE, *et al.* Cochrane Handbook for Systematic Reviews of Interventions. 2019.
- 19 Thomas J, Kneale D, McKenzie JE, et al. Determining the scope of the review and the questions it will address. In: Cochrane Handbook for Systematic Reviews of Interventions. 2019: 13–31.
- 20 Higgins JPT, Altman DG, Gøtzsche PC, *et al.* The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 2011;343:d5928.
- 21 Fewtrell MS, Kennedy K, Singhal A, et al. How much loss to followup is acceptable in long-term randomised trials and prospective studies? Arch Dis Child 2008;93:458–61.
- 22 Wan X, Wang W, Liu J, *et al*. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC Med Res Methodol* 2014;14:135.
- 23 Borenstein M, Hedges LV, Higgins JPT, et al. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods 2010;1:97–111.
- 24 Hedges LV, Olkin I. Statistical Methods for Meta-Analysis. Academic press, 2014.
- 25 Cohen J. Statistical Power Analysis for the Behavioral Sciences. Academic press, 2013.

<u>ð</u>

Open access

- 26 Higgins JPT, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med 2002;21:1539–58.
- 27 Deeks JJ, Higgins JPT, Altman DG, *et al*. Analysing data and undertaking meta-analyses. In: *Cochrane Handbook for Systematic Reviews of Interventions*. 2019: 241–84.
- 28 Sterne JAC, Sutton AJ, Ioannidis JPA, *et al*. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. *BMJ* 2011;343:bmj.d4002.
- 29 McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. *Res Synth Methods* 2021;12:55–61.
- 30 Hagberg JM, Montain SJ, Martin WH, et al. Effect of exercise training in 60- to 69-year-old persons with essential hypertension. Am J Cardiol 1989;64:348–53.
- 31 Kiyonaga A, Arakawa K, Tanaka H, et al. Blood pressure and hormonal responses to aerobic exercise. *Hypertension* 1985;7:125–31.
- 32 Urata H, Tanabe Y, Kiyonaga A, et al. Antihypertensive and volumedepleting effects of mild exercise on essential hypertension. *Hypertension* 1987;9:245–52.
- 33 Sikiru L, Okoye GC. Therapeutic effect of continuous exercise training program on serum creatinine concentration in men with hypertension: a randomized controlled trial. *Ghana Med J* 2014;48:135–42.
- 34 Martinelli B, Barrile SR, Arca EA, et al. Effect of aerobic exercise on plasma renin in overweight patients with hypertension. Arq Bras Cardiol 2010;95:91–8.
- 35 Sullivan PA, Grosch C, Lawless D, et al. Short-term strenuous exercise training: effects on blood pressure and hormonal levels in mild hypertension. Ir J Med Sci 1992;161:666–9.
- 36 Kinoshita A, Koga M, Matsusaki M, *et al.* Changes of dopamine and atrial natriuretic factor by mild exercise for hypertensives. *Clin Exp Hypertens A* 1991;13:1275–90.
- 37 Koga M, Ideishi M, Matsusaki M, et al. Mild exercise decreases plasma endogenous digitalislike substance in hypertensive individuals. *Hypertension* 1992;19:II231–6.

- 38 Matsusaki M, Ikeda M, Tashiro E, et al. Influence of workload on the antihypertensive effect of exercise. Clin Exp Pharmacol Physiol 1992;19:471–9.
- 39 Nelson L, Esler M, Jennings G, et al. EFFECT OF CHANGING LEVELS OF PHYSICAL ACTIVITY ON BLOOD-PRESSURE AND HAEMODYNAMICS IN ESSENTIAL HYPERTENSION. The Lancet 1986;328:473–6.
- 40 Oliveira VN de, Bessa A, Jorge MLMP, et al. The effect of different training programs on antioxidant status, oxidative stress, and metabolic control in type 2 diabetes. *Appl Physiol Nutr Metab* 2012;37:334–44.
- 41 Zaman GS, Abohashrh M, Ahmad I, et al. The Impact of Body Resistance Training Exercise on Biomedical Profile at High Altitude: A Randomized Controlled Trial. *Biomed Res Int* 2021;2021:6684167.
- 42 Szulińska M, Skrypnik D, Ratajczak M, et al. Effects of Endurance and Endurance-strength Exercise on Renal Function in Abdominally Obese Women with Renal Hyperfiltration: A Prospective Randomized Trial. *Biomed Environ Sci* 2016;29:706–12.
- 43 Trabelsi K, Stannard SR, Maughan RJ, et al. Effect of Resistance Training During Ramadan on Body Composition and Markers of Renal Function, Metabolism, Inflammation, and Immunity in Recreational Bodybuilders. Int J Sport Nutr Exerc Metab 2012;22:267–75.
- 44 Geyssant A, Geelen G, Denis C, *et al.* Plasma vasopressin, renin activity, and aldosterone: effect of exercise and training. *Eur J Appl Physiol Occup Physiol* 1981;46:21–30.
- 45 Passino C, Severino S, Poletti R, et al. Aerobic training decreases B-type natriuretic peptide expression and adrenergic activation in patients with heart failure. J Am Coll Cardiol 2006;47:1835–9.
- 46 Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitorassociated elevations in serum creatinine: is this a cause for concern? *Arch Intern Med* 2000;160:685–93.
- 47 Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020;383:1436–46.